NDAORALTABLET
Approved
Jul 2016
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
5
Data completeness
5/8 — Partial
RELISTOR (methylnaltrexone bromide) by Salix Pharmaceuticals is mu-opioid receptor. Approved for opioid-induced constipation (oic) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer, its treatment and 4 more indications. First approved in 2016.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RELISTOR (methylnaltrexone bromide) is an oral small-molecule peripheral mu-opioid receptor antagonist approved to treat opioid-induced constipation (OIC) in adults with chronic non-cancer pain and advanced illness. As a quaternary amine, it cannot cross the blood-brain barrier, allowing it to block opioid constipation effects in the GI tract while preserving central pain relief.
Peak4.7 years to LOE
Product is at peak lifecycle with moderate competitive pressure (8/10), indicating stable commercial demand and continued commercial team investment.
Mechanism of Action
mu-opioid receptor. As a quaternary amine, the ability of methylnaltrexone to cross the blood-brain barrier is restricted. This allows methylnaltrexone to function as a peripherally-acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the…
Worked on RELISTOR at Salix Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.